Patrick Wood
Stock Analyst at Morgan Stanley
(3.13)
# 1,247
Out of 5,090 analysts
117
Total ratings
51.11%
Success rate
1.24%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMDX TransMedics Group | Maintains: Equal-Weight | $123 → $135 | $136.51 | -1.11% | 3 | Dec 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Equal-Weight | $17 → $23 | $20.93 | +9.89% | 6 | Dec 2, 2025 | |
| RXST RxSight | Maintains: Equal-Weight | $9 → $10 | $12.66 | -21.01% | 3 | Dec 2, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $56 → $51 | $35.86 | +42.22% | 4 | Dec 2, 2025 | |
| DXCM DexCom | Upgrades: Overweight | $63 → $75 | $65.49 | +14.52% | 10 | Dec 2, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $197 → $210 | $193.83 | +8.34% | 6 | Dec 2, 2025 | |
| BAX Baxter International | Maintains: Underweight | $19 → $15 | $18.53 | -19.05% | 6 | Dec 2, 2025 | |
| BLCO Bausch + Lomb | Upgrades: Overweight | $14 → $21 | $16.81 | +24.93% | 9 | Dec 2, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $74 → $80 | $85.46 | -6.39% | 8 | Oct 30, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $125 → $130 | $97.50 | +33.33% | 7 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $84 → $76 | $81.40 | -6.63% | 6 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $84 → $80 | $80.70 | -0.87% | 5 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $276 → $295 | $262.94 | +12.19% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $81 | $86.26 | -6.10% | 9 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $80 → $103 | $85.43 | +20.57% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $110 → $72 | $108.49 | -33.63% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $191 → $173 | $120.46 | +43.62% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $304.49 | +4.11% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $10 | $3.01 | +232.23% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $25.44 | +45.47% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $117.33 | - | 5 | Dec 11, 2017 |
TransMedics Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $123 → $135
Current: $136.51
Upside: -1.11%
Tandem Diabetes Care
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $17 → $23
Current: $20.93
Upside: +9.89%
RxSight
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $12.66
Upside: -21.01%
PROCEPT BioRobotics
Dec 2, 2025
Maintains: Overweight
Price Target: $56 → $51
Current: $35.86
Upside: +42.22%
DexCom
Dec 2, 2025
Upgrades: Overweight
Price Target: $63 → $75
Current: $65.49
Upside: +14.52%
Becton, Dickinson and Company
Dec 2, 2025
Maintains: Overweight
Price Target: $197 → $210
Current: $193.83
Upside: +8.34%
Baxter International
Dec 2, 2025
Maintains: Underweight
Price Target: $19 → $15
Current: $18.53
Upside: -19.05%
Bausch + Lomb
Dec 2, 2025
Upgrades: Overweight
Price Target: $14 → $21
Current: $16.81
Upside: +24.93%
GE HealthCare Technologies
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $74 → $80
Current: $85.46
Upside: -6.39%
Boston Scientific
Oct 23, 2025
Maintains: Overweight
Price Target: $125 → $130
Current: $97.50
Upside: +33.33%
Aug 28, 2025
Maintains: Equal-Weight
Price Target: $84 → $76
Current: $81.40
Upside: -6.63%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $84 → $80
Current: $80.70
Upside: -0.87%
Aug 8, 2025
Maintains: Overweight
Price Target: $276 → $295
Current: $262.94
Upside: +12.19%
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $75 → $81
Current: $86.26
Upside: -6.10%
Jul 15, 2025
Upgrades: Overweight
Price Target: $80 → $103
Current: $85.43
Upside: +20.57%
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $108.49
Upside: -33.63%
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $120.46
Upside: +43.62%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $304.49
Upside: +4.11%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $3.01
Upside: +232.23%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $25.44
Upside: +45.47%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $117.33
Upside: -